Literature DB >> 24876151

Flavonoids from each of the six structural groups reactivate BRM, a possible cofactor for the anticancer effects of flavonoids.

Bhaskar Kahali1, Stefanie B Marquez1, Kenneth W Thompson1, Jinlong Yu1, Sarah J B Gramling1, Li Lu2, Aaron Aponick3, David Reisman4.   

Abstract

Flavonoids have been extensively studied and are well documented to have anticancer effects, but it is not entirely known how they impact cellular mechanisms to elicit these effects. In the course of this study, we found that a variety of different flavonoids readily restored Brahma (BRM) in BRM-deficient cancer cell lines. Flavonoids from each of the six different structural groups were effective at inducing BRM expression as well as inhibiting growth in these BRM-deficient cancer cells. By blocking the induction of BRM with shRNA, we found that flavonoid-induced growth inhibition was BRM dependent. We also found that flavonoids can restore BRM functionality by reversing BRM acetylation. In addition, we observed that an array of natural flavonoid-containing products both induced BRM expression as well as deacetylated the BRM protein. We also tested two of the BRM-inducing flavonoids (Rutin and Diosmin) at both a low and a high dose on the development of tumors in an established murine lung cancer model. We found that these flavonoids effectively blocked development of adenomas in the lungs of wild-type mice but not in that of BRMnull mice. These data demonstrate that BRM expression and function are regulated by flavonoids and that functional BRM appears to be a prerequisite for the anticancer effects of flavonoids both in vitro and in vivo.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24876151      PMCID: PMC4178464          DOI: 10.1093/carcin/bgu117

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  73 in total

1.  Pomiferin, histone deacetylase inhibitor isolated from the fruits of Maclura pomifera.

Authors:  Il Hong Son; Ill-Min Chung; Sung Ik Lee; Hyun Duk Yang; Hyung-In Moon
Journal:  Bioorg Med Chem Lett       Date:  2007-06-26       Impact factor: 2.823

2.  Baicalin is anti-inflammatory in cigarette smoke-induced inflammatory models in vivo and in vitro: A possible role for HDAC2 activity.

Authors:  Lulu Li; Hong Bao; Jinfeng Wu; Xiaohong Duan; Baojun Liu; Jing Sun; Weiyi Gong; Yubao Lv; Hongying Zhang; Qingli Luo; Xiao Wu; Jingcheng Dong
Journal:  Int Immunopharmacol       Date:  2012-03-13       Impact factor: 4.932

3.  Effect of silibinin on the growth and progression of primary lung tumors in mice.

Authors:  Rana P Singh; Gagan Deep; Manesh Chittezhath; Manjinder Kaur; Lori D Dwyer-Nield; Alvin M Malkinson; Rajesh Agarwal
Journal:  J Natl Cancer Inst       Date:  2006-06-21       Impact factor: 13.506

4.  The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma.

Authors:  Zsuzsanna Lichner; Andreas Scorilas; Nicole M A White; Andrew H Girgis; Lora Rotstein; Kimberly C Wiegand; Ashraf Latif; Christina Chow; David Huntsman; George M Yousef
Journal:  Am J Pathol       Date:  2013-02-12       Impact factor: 4.307

5.  Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.

Authors:  M F Decristofaro; B L Betz; C J Rorie; D N Reisman; W Wang; B E Weissman
Journal:  J Cell Physiol       Date:  2001-01       Impact factor: 6.384

6.  Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

Authors:  H Sedlacek; J Czech; R Naik; G Kaur; P Worland; M Losiewicz; B Parker; B Carlson; A Smith; A Senderowicz; E Sausville
Journal:  Int J Oncol       Date:  1996-12       Impact factor: 5.650

7.  Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.

Authors:  G Liu; S Gramling; D Munoz; D Cheng; A K Azad; M Mirshams; Z Chen; W Xu; H Roberts; F A Shepherd; M S Tsao; D Reisman
Journal:  Oncogene       Date:  2011-04-11       Impact factor: 9.867

8.  Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Authors:  Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

9.  Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer.

Authors:  Junya Fukuoka; Takeshi Fujii; Joanna H Shih; Tatiana Dracheva; Daoud Meerzaman; Audrey Player; Kyeong Hong; Sharon Settnek; Ajay Gupta; Kenneth Buetow; Stephen Hewitt; William D Travis; Jin Jen
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

10.  Discovery of BRM Targeted Therapies: Novel Reactivation of an Anti-cancer Gene.

Authors:  Sarah Gramling; David Reisman
Journal:  Lett Drug Des Discov       Date:  2011-01-01       Impact factor: 1.150

View more
  10 in total

1.  BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.

Authors:  Geoffrey Liu; Sinead Cuffe; Shermi Liang; Abul Kalam Azad; Lu Cheng; Yonathan Brhane; Xin Qiu; David W Cescon; Jeffrey Bruce; Zhuo Chen; Dangxiao Cheng; Devalben Patel; Brandon C Tse; Scott A Laurie; Glenwood Goss; Natasha B Leighl; Rayjean Hung; Penelope A Bradbury; Lesley Seymour; Frances A Shepherd; Ming Sound Tsao; Bingshu E Chen; Wei Xu; David N Reisman
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

2.  SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior.

Authors:  Jennifer L Sauter; Rondell P Graham; Brandon T Larsen; Sarah M Jenkins; Anja C Roden; Jennifer M Boland
Journal:  Mod Pathol       Date:  2017-06-23       Impact factor: 7.842

3.  Induction of functional Brm protein from Brm knockout mice.

Authors:  Kenneth W Thompson; Stefanie B Marquez; Li Lu; David Reisman
Journal:  Oncoscience       Date:  2015-04-18

Review 4.  Beyond Mutations: Additional Mechanisms and Implications of SWI/SNF Complex Inactivation.

Authors:  Stefanie B Marquez; Kenneth W Thompson; Li Lu; David Reisman
Journal:  Front Oncol       Date:  2015-02-27       Impact factor: 6.244

5.  Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.

Authors:  Grzegorz J Korpanty; Lawson Eng; Xin Qiu; Olusola Olusesan Faluyi; Daniel J Renouf; Dangxiao Cheng; Devalben Patel; Zhuo Chen; Brandon C Tse; Jennifer J Knox; Lorin Dodbiba; Jennifer Teichman; Abul Kalam Azad; Rebecca Wong; Gail Darling; David Reisman; Sinead Cuffe; Geoffrey Liu; Wei Xu
Journal:  Oncotarget       Date:  2017-04-25

6.  Mechanism of BRG1 silencing in primary cancers.

Authors:  Stefanie B Marquez-Vilendrer; Kenneth Thompson; Li Lu; David Reisman
Journal:  Oncotarget       Date:  2016-08-30

7.  Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development.

Authors:  Stefanie B Marquez-Vilendrer; Sudhir K Rai; Sarah Jb Gramling; Li Lu; David N Reisman
Journal:  Oncoscience       Date:  2016-11-17

8.  BRG1 and BRM loss selectively impacts RB and P53, respectively: BRG1 and BRM have differential functions in vivo.

Authors:  Stefanie B Marquez-Vilendrer; Sudhir K Rai; Sarah Jb Gramling; Li Lu; David N Reisman
Journal:  Oncoscience       Date:  2016-12-21

9.  Rutin mediated targeting of signaling machinery in cancer cells.

Authors:  Aliye Aras Perk; Iryna Shatynska-Mytsyk; Yusuf Can Gerçek; Kadir Boztaş; Mevzule Yazgan; Sundas Fayyaz; Ammad Ahmad Farooqi
Journal:  Cancer Cell Int       Date:  2014-11-30       Impact factor: 5.722

10.  Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type.

Authors:  Petar Jelinic; Brooke A Schlappe; Niamh Conlon; Jill Tseng; Narciso Olvera; Fanny Dao; Jennifer J Mueller; Yaser Hussein; Robert A Soslow; Douglas A Levine
Journal:  Mod Pathol       Date:  2015-11-13       Impact factor: 7.842

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.